Credit Suisse Group set a €16.50 ($19.19) price target on Rhoen Klinikum (ETR:RHK) in a report published on Wednesday, Borsen Zeitung reports. The brokerage currently has a sell rating on the stock.
Several other research firms have also recently issued reports on RHK. Berenberg Bank set a €26.20 ($30.47) price objective on shares of Rhoen Klinikum and gave the stock a neutral rating in a research report on Tuesday, July 30th. Independent Research set a €25.50 ($29.65) price objective on shares of Rhoen Klinikum and gave the stock a neutral rating in a research report on Monday, August 5th. Three investment analysts have rated the stock with a sell rating and three have given a hold rating to the company. The stock presently has a consensus rating of Hold and a consensus price target of €21.95 ($25.52).
RHK stock traded down €0.38 ($0.44) during midday trading on Wednesday, hitting €19.00 ($22.09). The company’s stock had a trading volume of 21,126 shares, compared to its average volume of 43,281. The company has a quick ratio of 1.66, a current ratio of 1.80 and a debt-to-equity ratio of 9.80. Rhoen Klinikum has a 52-week low of €17.92 ($20.84) and a 52-week high of €27.40 ($31.86). The firm has a market capitalization of $1.27 billion and a P/E ratio of 24.55. The firm has a 50-day simple moving average of €19.51 and a 200-day simple moving average of €23.42.
RHÖN-KLINIKUM Aktiengesellschaft, together with its subsidiaries, builds, acquires, and operates primarily acute-care hospitals in Germany. Its hospitals offer treatment services primarily in the areas of cardiovascular, neurology, oncology, pulmonology, orthopedic, accident surgery; rehabilitation and nursing services to the elderly; and thoracic, tumors, and psychosomatic, as well as spinal, column, and joints diseases.
Further Reading: Monthly Dividend Stocks
Receive News & Ratings for Rhoen Klinikum Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rhoen Klinikum and related companies with MarketBeat.com's FREE daily email newsletter.